RedDress Ltd.

We are excited to share that ActiGraft Pro has been added to the Wound Care Advantage (WCA) Formulary after a comprehensive evaluation by the WCA Product Council, a team of wound care experts. The WCA Product Council reviews products for safety, effectiveness, and accessibility for wound centers. https://lnkd.in/g8REx5qM WCA’s mission is to eliminate unnecessary amputations in our lifetime and believes every community should have access to a comprehensive, financially sustainable wound care program. With 20+ years of experience, WCA supports a national network of wound centers with a strong focus on reducing costs and improving patient outcomes. The centers have access to the formulary for comprehensive education and information, allowing providers to make well-informed decisions that best support their patients’ care. Since receiving FDA clearance and a CE Mark in 2020, ActiGraft has helped over 7,000 patients across the spectrum of healthcare facilities in the USA and 30 other countries. Let’s connect to explore the next steps with ActiGraft at your facility. #HealingisinourBlood #ActiGraft #WoundCare #WoundCareInnovation #Woundle #WoundHealing #WoundCenter #WoundCareCenter #WoundProgram #Outpatient #OutpatientWoundCare #WCA #TheWCA

It's a wrap! Thank you to all who dropped by our booth at SAWC Fall in Las Vegas and discussed the recently published ActiGraft's multinational RCT-backed landmark healing results in treating chronic wounds. We look forward to connecting with you at your clinics and supporting you and your patients as we embark on the ActiGraft healing journey together. Learn more: https://lnkd.in/gYS6NAD5 #HealingisinourBlood #chronicwounds #woundmangement #ActiGraftPro #clinicalevidence #patientoutcomes

SAWC Fall Day 1: What a great start for us! A very special thanks to the Frank N Lizzie Show discussing the blood-derived products category, and ActiGraft at the SAWC Live Studio today! In this episode,Dr. Rob Snyder, DPM, MSc, MBA, CWSP, FFPM RCPS(Glasg) and Kathleen D. Schaum discuss ActiGraft's latest RCT's published results - clinically proven fast and efficacious healing of chronic DFU's, and the significance of its National Coverage Determination status (NCD 270.3). Stay tuned as the episode will be live soon on their channel. Elizabeth Faust Frank Aviles, PT,CWS,FACCWS,CLT-LANA,ALM,AWCC Visit us at Booth 210 to learn more about the power of ActiGraft Whole Blood Clot. https://lnkd.in/gYS6NAD5 #SAWCFall2024 #ChronicWoundCare #FrankNLizzieShow

🍂 Yes, fall colors are in the air which also means it's that awaited SAWC at Vegas! We are ready to meet you at Booth#210 to discuss ActiGraft's latest multinational RCT results (across 16 sites) and share its exceptional efficacy data in healing chronic neuropathic foot ulcers. Learn more about the RCT and superior healing of ActiGraft Whole Blood Clot here: https://lnkd.in/gYS6NAD5 #Bethedifferencemaker #Healinginnovations #SAWC #SAWC2024 #NPIAP #Chronicwounds #DFU #DiabeticFootUlcers #HealingisinourBlood #nocentrifuge #notaskinsubstitute

**New Publication Alert** Journal of Wound Care, 2 September 2024-Volume 33, Issue 9: Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomized controlled trial In this multicenter, prospective, blinded assessor RCT, ActiGraft Pro treatment achieved a significantly higher 51% healing rate compared to the 18% in the control group in a shorter mean time to heal and higher durability of wound closure. Diabetic Foot Ulcers (DFUs) present a significant global health challenge, resulting in high morbidity and economic costs. Current available treatments often fail to achieve satisfactory healing rates, highlighting the need for such novel therapies. 🗺 The multinational study included 119 patients at 13 sites in the US, 3 in RSA, and 1 in Turkey. Learn more on this promising new treatment created from patients own blood: https://lnkd.in/gJaYrEdS #ActiGraft #HealingisinOurBlood #Chronicwounds #DiabeticFootUlcers #Healthcareinnovations #Hope

RedDress' multicenter, prospective, blinded assessor RCT showing significant benefits of using ActiGraft Pro to treat chronic neuropathic DFUs compared to the best practice SoC has been published in the Journal of Wound Care. Not only ActiGraft Pro treatment achieved a 51% healing rate compared to 18% in the control group, but it also showed a shorter time to heal and greater durability of wound closure: 71% of healed wounds remained closed vs. 55% with standard care*, demonstrating better long-term healing durability. The multinational study included 119 patients at 13 sites in the US, three sites in South Africa, and one site in Turkey. Learn more: https://lnkd.in/gjyEGPQs #ActiGraft #HealingisinOurBlood #Chronicwounds #DiabeticFootUlcers #Healthcareinnovations

Hot off the press! Just published in the September 2024 Journal of Wound Care, our first randomized controlled trial results show significant benefits of using ActiGraft PRO® to treat chronic neuropathic diabetic foot ulcers compared to the best practice standard of care. The ActiGraft Pro treatment resulted in a 51% healing rate compared to 18% in the control group and showed a shorter time to heal with a greater durability of wound closure. The study, “A Multicenter, Prospective, Randomized, Controlled Trial Comparing the Safety and Efficiency of Autologous Whole Blood Clot to Standard of Care in Patients with Chronic Diabetic Foot Ulcers,” included 119 patients at 13 sites in the US, 3 sites in South Africa and 1 in Turkey. These results underscore ActiGraft's effectiveness in enhancing patient outcomes and delivering a promising advancement in wound management. Learn more: Efficacy and safety of autologous whole blood clot in diabetic foot ulcers: a randomized controlled trial | Journal of Wound Care https://lnkd.in/gjyEGPQs #ActiGraft #RedDress #HealingisinOurBlood #Chronicwounds #Woundmanagement #DiabeticFootUlcers #Innovation

Excitement is in the air as we gear up for a relaxing, reflective, and empowering Labor Day weekend. And it is also because the new month is bringing big news for RedDress and our clinicians. The results of a rigorous, multinational randomized controlled trial using ActiGraft PRO® will be published in the Journal of Wound Care (JWC). Check back after the weekend to learn more about how ActiGraftPRO harnesses the power of a patient's own whole blood to accelerate natural healing in diabetic foot ulcers. #ActiGraft #RedDress #HealingisinOurBlood #Chronicwounds #Woundmanagement #woundcare #patientcare #JWC #HealthCareInnovation

RedDress' ActiGraft shows promising outcomes in treating Pilonidal Sinus (PNS). PNS is caused by an infection in the sacrococcygeal area triggered by hair particle accumulation in skin tunnels. As reported in Techniques in Coloproctology, a Phase II study of RD2 Ver.02, a novel autologous whole-blood clot product coupled with minimally invasive procedure, achieved a 92% healing rate at 6 months, with no device-related adverse events. This innovative approach could mark a significant advancement in treating PNS, offering a safe and effective solution. Learn more about this study here: https://lnkd.in/gaYeKuH7 Reaffirming our commitment and dedication to continued investment in R&D, delivering advanced wound healing solutions that enhance quality of life for patients. #Chronicwounds #HealingisinourBlood #woundmanagement #ASCRS

#APMA2024 Supporting the association with its goal of advancing foot and ankle medicine and surgery. Thank you to member podiatrists! We welcome you all to our Booth #714 to discuss ActiGraft Pro, our innovative autologous wound care solution that heals chronic wounds and ulcers. Learn more about how it harnesses the power of whole blood to accelerate natural healing in the body. #Actigraft #RedDress #HealingisinOurBlood #Chronicwounds #Woundmanagement #diabeticFootUlcers